This observation implies that ACACA-mediated metabolic reprogramming may be involved in osimertinib resistance of lung adenocarcinoma; however, the current findings alone are insufficient to establish a definitive causal relationship between ACACA and this drug-resistant phenotype. Here, ACACA is linked to lung adenocarcinoma.